EUVIMEDEUVIMED entdecken
Open Access

Exposure to Sedation and Analgesia Medications: Short-term Cognitive Outcomes in Pediatric Critical Care Survivors With Acquired Brain Injury

Kurt M Drury iD, Trevor A Hall, Benjamin Orwoll, Sweta Adhikary, Aileen Kirby, Cydni N Williams

Journal of Intensive Care Medicine · 2024-04 · 39 (4) · 374-386

DOI: 10.1177/08850666231210261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Intensive Care Medicine, online erschienen am 26.10.2023. Verfasst von Kurt M Drury und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Critical Care, Oregon Health & Science University, Portland, OR, USA. Hauptthemen laut MEDLINE: Ketamine, Analgesia, Brain Injuries. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart Lung and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objective: Pediatric intensive care unit (PICU) survivors risk significant cognitive morbidity, particularly those with acquired brain injury (ABI) diagnoses. Studies show sedative and analgesic medication may potentiate neurologic injury, but few studies evaluate impact on survivor outcomes. This study aimed to evaluate whether exposures to analgesic and sedative medications are associated with worse neurocognitive outcome.

Methods

A retrospective cohort study was conducted of 91 patients aged 8 to 18 years, undergoing clinical neurocognitive evaluation approximately 1 to 3 months after PICU discharge. Electronic health data was queried for sedative and analgesic medication exposures, including opioids, benzodiazepines, propofol, ketamine, and dexmedetomidine. Doses were converted to class equivalents, evaluated by any exposure and cumulative dose exposure per patient weight. Cognitive outcome was derived from 8 objective cognitive assessments with an emphasis on executive function skills using Principal Components Analysis. Then, linear regression was used to control for baseline cognitive function estimates to calculate a standardized residualized neurocognitive index (rNCI) z-score. Multivariable linear regression evaluated the association between rNCI and medication exposure controlling for covariates. Significance was defined as P < .05.

Results

Most ( n = 80; 88%) patients received 1 or more study medications. Any exposure and higher cumulative doses of benzodiazepine and ketamine were significantly associated with worse rNCI in bivariate analyses. When controlling for Medicaid, preadmission comorbid conditions, length of stay, delirium, and receipt of other medication classes, receipt of benzodiazepine was associated with significantly worse rNCI ( β-coefficient = −0.48, 95% confidence interval = −0.88, −0.08).

Conclusions

Exposure to benzodiazepines was independently associated with worse acute phase cognitive outcome using objective assessments focused on executive function skills when controlling for demographic and illness characteristics. Clinician decisions regarding medication regimens in the PICU may serve as a modifiable factor to improve outcomes. Additional inquiry into associations with long-term cognitive outcome and optimal medication regimens is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineAnalgesiaBrain InjuriesHumansChildRetrospective StudiesHypnotics and SedativesAnalgesicsBenzodiazepinesCritical CareIntensive Care Units, PediatricCognitionSurvivorsRespiration, Artificial

Stichwörter der Autor:innen

analgesiabrainbrain injurieschildexecutive functionhypnotics and sedativesintensive care unitspediatricretrospective studiessurvivors

Substanzen

KetamineHypnotics and SedativesAnalgesicsBenzodiazepines

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Critical Care, Oregon Health & Science University, Portland, OR, USA.
  • Pediatric Critical Care and Neurotrauma Recovery Program, Oregon Health & Science University, Portland, OR, USA.
  • Department of Pediatrics, Division of Pediatric Psychology, Oregon Health & Science University, Portland, OR, USA.
  • School of Medicine, Oregon Health and Science University, Portland, OR, USA.

ORCID-Profile: Kurt M Drury

Förderung

  • NHLBI NIH HHS
  • National Heart Lung and Blood Institute

Zitieren

APA

Drury, K. M., Hall, T. A., Orwoll, B., Adhikary, S., Kirby, A., & Williams, C. N. (2024). Exposure to Sedation and Analgesia Medications: Short-term Cognitive Outcomes in Pediatric Critical Care Survivors With Acquired Brain Injury. Journal of Intensive Care Medicine, 39(4), 374-386. https://doi.org/10.1177/08850666231210261

Vancouver

Drury KM, Hall TA, Orwoll B, Adhikary S, Kirby A, Williams CN. Exposure to Sedation and Analgesia Medications: Short-term Cognitive Outcomes in Pediatric Critical Care Survivors With Acquired Brain Injury. Journal of Intensive Care Medicine. 2024;39(4):374-386. doi:10.1177/08850666231210261

BibTeX
@article{Drury2024,
  author = {Drury, Kurt M and Hall, Trevor A and Orwoll, Benjamin and Adhikary, Sweta and Kirby, Aileen and Williams, Cydni N},
  title = {Exposure to Sedation and Analgesia Medications: Short-term Cognitive Outcomes in Pediatric Critical Care Survivors With Acquired Brain Injury},
  journal = {Journal of Intensive Care Medicine},
  year = {2024},
  volume = {39},
  number = {4},
  pages = {374--386},
  doi = {10.1177/08850666231210261}
}
Kostenlos starten →